Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

1. Management of osteoporosis and the prevention of fragility fractures

Management of osteoporosis and the prevention of fragility fractures Management of osteoporosis and the prevention of fragility fractures A national clinical guideline First published March 2015 Revised June 2020 Revised January 2021 SIGN142Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta (...) used by Scottish Intercollegiate Guidelines Network to produce clinical guidelines. The accreditation term is valid until 30 June 2020 and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2019 edition (https://www.sign.ac.uk/assets/sign50_2019.pdf). More information on accreditation can be viewed at www.nice.org.uk/accreditationScottish Intercollegiate Guidelines Network Management of osteoporosis and the prevention of fragility

2021 SIGN

2. Romosozumab (Evenity) - treatment of severe osteoporosis

Romosozumab (Evenity) - treatment of severe osteoporosis 1 Published 09 November 2020 1 SMC2280 romosozumab 105mg solution for injection in pre- filled pen (Evenity®) UCB Pharma Ltd 9 October 2020 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission romosozumab (Evenity®) is accepted (...) for restricted use within NHSScotland. Indication under review: treatment of severe osteoporosis in postmenopausal women at high risk of fracture. SMC restriction: to use in patients who have experienced a fragility fracture and are at imminent risk of another fragility fracture (within 24 months). In a phase III study in post-menopausal women with osteoporosis who were at high risk of fracture, romosozumab for 12 months followed by an oral bisphosphanate reduced the risk of fractures compared with an oral

2020 Scottish Medicines Consortium

3. AACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

AACE Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 26 (Suppl 1) May 2020 1 Copyright © 2020 AACE Clinical Practice Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE Pauline M. Camacho, MD, FACE 1 ; Steven M. Petak, MD, JD, FACP , FCLM, MACE, CCD 2 ; Neil Binkley, MD 3 ; Dima L (...) , 2020 From the 1 Guideline Task Force Co-Chair, Professor of Medicine, Director, Loyola University Osteoporosis and Metabolic Bone Disease Center, Maywood, Illinois, 2 Guideline Task Force Co-Chair, Associate Clinical Professor, Weill-Cornell Medical College, Division Head and Service Chief, Endocrinology, Houston Methodist Hospital, Charles and Anne Duncan Centennial Clinical Academic Scholar in Endocrinology, Houston, Texas, 3 Professor of Medicine, Divisions of Endocrinology and Geriatrics

2020 American Association of Clinical Endocrinologists

4. Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis

Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis ENDOCRINE PRACTICE Vol 26 (Suppl 1) May 2020 1 Copyright © 2020 AACE Clinical Practice Guidelines AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS/ AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS— 2020 UPDATE Pauline M. Camacho, MD, FACE 1 ; Steven M. Petak, MD, JD, FACP , FCLM, MACE, CCD 2 ; Neil Binkley, MD 3 ; Dima L. Diab (...) From the 1 Guideline Task Force Co-Chair, Professor of Medicine, Director, Loyola University Osteoporosis and Metabolic Bone Disease Center, Maywood, Illinois, 2 Guideline Task Force Co-Chair, Associate Clinical Professor, Weill-Cornell Medical College, Division Head and Service Chief, Endocrinology, Houston Methodist Hospital, Charles and Anne Duncan Centennial Clinical Academic Scholar in Endocrinology, Houston, Texas, 3 Professor of Medicine, Divisions of Endocrinology and Geriatrics, University

2020 American Association of Clinical Endocrinologists

5. Romosozumab (osteoporosis) - Addendum to Commission A20-24

Romosozumab (osteoporosis) - Addendum to Commission A20-24 1 Translation of addendum A20-67 Romosozumab (Osteoporose) – Addendum zum Auftrag A20-24 (Version 1.0; Status: 14 August 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 14 August 2020 1.0 Commission: A20-67 Version: Status: IQWiG Reports – Commission No. A20-67 Romosozumab (osteoporosis (...) ) – Addendum to Commission A20-24 1 Addendum A20-67 Version 1.0 Romosozumab – Addendum to Commission A20-24 14 August 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Romosozumab (osteoporosis) – Addendum to Commission A20-24 Commissioning agency Federal Joint Committee Commission awarded on 28 July 2020 Internal Commission No. A20-67 Address of publisher Institut für Qualität und Wirtschaftlichkeit

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

6. Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V

Romosozumab (osteoporosis) - Benefit assessment according to §35a Social Code Book V 1 Translation of Sections 2.1 to 2.5 of the dossier assessment Romosozumab (Osteoporose) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 10 June 2020). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. A20-24 Romosozumab (...) (osteoporosis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A20-24 Version 1.0 Romosozumab (osteoporosis) 10 June 2020 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher Institute for Quality and Efficiency in Health Care Topic Romosozumab (osteoporosis) – Benefit assessment according to §35a Social Code Book V Commissioning agency Federal Joint Committee Commission awarded on 11 March 2020 Internal Commission No. A20

2020 Institute for Quality and Efficiency in Healthcare (IQWiG)

7. Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study. (Abstract)

Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis : A Population-Based Cohort Study. Denosumab is effective for osteoporosis, but discontinuation leads to rapid reversal of its therapeutic effect.To estimate the risk for fracture among users of denosumab who delayed subsequent doses compared with users who received doses on time.Population-based cohort study.The Health Improvement Network U.K. primary care database, 2010 to 2019.Persons aged 45 years or older who

2020 Annals of Internal Medicine

8. Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial Full Text available with Trip Pro

Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set (...) Permalink Copy Page navigation BMC Musculoskelet Disord Actions . 2020 Jul 18;21(1):471. doi: 10.1186/s12891-020-03495-9. Physical fitness in older women with osteoporosis and vertebral fracture after a resistance and balance exercise programme: 3-month post-intervention follow-up of a randomised controlled trial , , , , , Affiliations Expand Affiliations 1 Institute of Physiotherapy, Faculty of Health Sciences, Oslo Metropolitan University, Oslo, Norway. bsugland@oslomet.no. 2 Institute

2020 EvidenceUpdates

9. Management of osteoporosis and the prevention of fragility fractures

Management of osteoporosis and the prevention of fragility fractures Management of osteoporosis and the prevention of fragility fractures A national clinical guideline First published March 2015 Revised edition published June 2020 SIGN142Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta (...) used by Scottish Intercollegiate Guidelines Network to produce clinical guidelines. The accreditation term is valid until 30 June 2020 and is applicable to guidance produced using the processes described in SIGN 50: a guideline developer’s handbook, 2019 edition (https://www.sign.ac.uk/assets/sign50_2019.pdf). More information on accreditation can be viewed at www.nice.org.uk/accreditationScottish Intercollegiate Guidelines Network Management of osteoporosis and the prevention of fragility

2020 SIGN

10. Teriparatide (Osnuvo) - osteoporosis

Teriparatide (Osnuvo) - osteoporosis Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written for approved after September 1, 2012

2020 Health Canada - Drug and Health Product Register

11. Denosumab (Prolia) and steroid-induced osteoporosis

Denosumab (Prolia) and steroid-induced osteoporosis Prescrire IN ENGLISH - Spotlight ''Denosumab (Prolia°) and steroid-induced osteoporosis'', 1 April 2020 {1} {1} {1} | | > > > Denosumab (Prolia°) and steroid-induced osteoporosis Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the April issue of Prescrire International: Denosumab (Prolia (...) °) and steroid-induced osteoporosis FREE DOWNLOAD Denosumab (Prolia°) has an unfavourable harm-benefit balance in the prevention of osteoporotic fractures. It has also been authorised in the prevention of osteoporosis induced by prolonged corticosteroid therapy. How do Prescrire's editors rate denosumab in this situation? Full text available for free download. Prescrire's rating NOT ACCEPTABLE Denosumab has not been shown to prevent clinical fractures, but it has many adverse effects that can be severe

2020 Prescrire

12. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Full Text available with Trip Pro

Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic ') We use cookies to enhance your experience on our website.By continuing to use our website, you are agreeing to our use of cookies. You can change your cookie settings at any time. Navbar Search Filter Mobile (...) Microsite Search Term search filter search input Article Navigation Close mobile search navigation Article Navigation March 2020 Article Contents Article Navigation Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update Dolores Shoback Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, Department of Medicine , San Francisco, California Department of Medicine, University of California San Francisco , San Francisco, California Search

2020 The Endocrine Society

13. Osteoporosis - prevention of fragility fractures: Calcium and colecalciferol (vitamin D3) preparations

Osteoporosis - prevention of fragility fractures: Calcium and colecalciferol (vitamin D3) preparations Calcium and colecalciferol (vitamin D3) preparations | Prescribing information | Osteoporosis - prevention of fragility fractures | CKS | NICE Search CKS… Menu Calcium and colecalciferol (vitamin D3) preparations Osteoporosis - prevention of fragility fractures: Calcium and colecalciferol (vitamin D3) preparations Last revised in 2016 Calcium and colecalciferol (vitamin D3) preparations What

2020 NICE Clinical Knowledge Summaries

14. Osteoporosis - prevention of fragility fractures: Scenario: Management

Osteoporosis - prevention of fragility fractures: Scenario: Management Scenario: Management | Management | Osteoporosis - prevention of fragility fractures | CKS | NICE Search CKS… Menu Scenario: Management Osteoporosis - prevention of fragility fractures: Scenario: Management Last revised in 2016 Scenario: Management How should I manage fragility fracture risk scores? For people at high risk of fragility fracture For people whose fracture risk is above the recommended threshold, offer a dual (...) These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline Osteoporosis: assessing the risk of fragility fracture [ ] and the Scottish Intercollegiate Guidelines Network (SIGN) guideline Management of osteoporosis and the prevention of fragility fractures [ ]. What drug treatments are recommended for people at high risk of osteoporotic fracture? If bone-sparing treatment is recommended, prescribe a bisphosphonate (alendronate 10 mg once daily or 70 mg once weekly

2020 NICE Clinical Knowledge Summaries

15. Osteoporosis - prevention of fragility fractures: Scenario: Assessment

Osteoporosis - prevention of fragility fractures: Scenario: Assessment Scenario: Assessment | Management | Osteoporosis - prevention of fragility fractures | CKS | NICE Search CKS… Menu Scenario: Assessment Osteoporosis - prevention of fragility fractures: Scenario: Assessment Last revised in 2016 Scenario: Assessment Who should I assess for fragility fracture risk? Identify high-risk groups of people to assess fragility fracture risk. These groups should include: All women aged 65 years (...) and over, and all men aged 75 years and over. All women aged 50–64 years and all men aged 50–74 years who have any of the following risk factors: A previous osteoporotic fragility fracture. Current use or frequent recent use of oral corticosteroids. History of falls. Low body mass index (less than 18.5 kg/m 2 Smoker. Alcohol intake of more than 14 units per week. A secondary cause of osteoporosis, including: Hypogonadism in either sex, including untreated premature menopause (menopause before 40 years

2020 NICE Clinical Knowledge Summaries

16. Romosozumab (Evenity) - treatment of osteoporosis in postmenopausal women at high risk for fracture

Romosozumab (Evenity) - treatment of osteoporosis in postmenopausal women at high risk for fracture Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

17. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study (Abstract)

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study Odanacatib, a cathepsin K inhibitor, reduces bone resorption while maintaining bone formation. Previous work has shown that odanacatib increases bone mineral density in postmenopausal women with low bone mass. We aimed to investigate the efficacy and safety of odanacatib to reduce fracture risk in postmenopausal women (...) , more than one vertebral fracture, or a T-score of less than -4·0 at the total hip or femoral neck were not eligible unless they were unable or unwilling to use approved osteoporosis treatment. Participants were randomly assigned (1:1) to either oral odanacatib (50 mg once per week) or matching placebo. Randomisation was done using an interactive voice recognition system after stratification for previous radiographic vertebral fracture, and treatment was masked to study participants, investigators

2019 EvidenceUpdates

18. Romosozymab (Evenity) - Osteoporosis

Romosozymab (Evenity) - Osteoporosis Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing

2019 Health Canada - drugs and medical devices

19. Diagnosis of osteoporosis in statin-treated patients is dose-dependent Full Text available with Trip Pro

Diagnosis of osteoporosis in statin-treated patients is dose-dependent Whether HMG-CoA-reductase inhibition, the main mechanism of statins, plays a role in the pathogenesis of osteoporosis, is not entirely known so far. Consequently, this study was set out to investigate the relationship of different kinds and dosages of statins with osteoporosis, hypothesising that the inhibition of the synthesis of cholesterol could influence sex-hormones and therefore the diagnosis of osteoporosis.Medical (...) claims data of all Austrians from 2006 to 2007 was used to identify all patients treated with statins to compute their daily defined dose averages of six different types of statins. We applied multiple logistic regression to analyse the dose-dependent risks of being diagnosed with osteoporosis for each statin individually.In the general study population, statin treatment was associated with an overrepresentation of diagnosed osteoporosis compared with controls (OR: 3.62, 95% CI 3.55 to 3.69, p<0.01

2019 EvidenceUpdates

20. Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines

Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines | CADTH.ca Find the information you need Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Duration of Bisphosphonate Treatment for Patients with Osteoporosis: Clinical Evidence and Guidelines Last updated: August 22, 2019 Project Number (...) : RA1059-000 Product Line: Research Type: Drug Report Type: Reference List Result type: Report Question What is the clinical evidence for varying treatment duration and courses of bisphosphonates for osteoporosis? What are the evidence-based guidelines regarding length of treatment with bisphosphonates for osteoporosis? Key Message One health technology assessment, six systematic reviews (one with meta-analyses), three randomized controlled trials, and five non-randomized studies were identified

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review